60 Degrees Pharmaceuticals (SXTP) Stock: Buy, Sell, or Hold?
SXTP - 60 Degrees Pharmaceuticals, Inc. Common Stock
$0.90
-0.03 (-3.23%)
▼
5d:
-3.24%
30d:
-20.35%
90d:
-34.78%
HOLD
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When SXTP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SXTP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SXTP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SXTP is currently trading at $0.90, which is considered oversold relative to its 30-day fair value range of $0.98 to $1.17.
Technical Outlook: Technically, SXTP is in a strong downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: SXTP scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.70 (+311.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SXTP is in a strong downtrend. The price is currently testing key support at $0.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: SXTP scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $3.70 (+311.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.98 -
$1.17
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 311.1% below Wall St target ($3.70)
- CAUTION: Bottoming setup, but lagging the sector by 20% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$0.98 -
$1.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.90
Resistance Level
$1.12
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.25
Wall Street Target
$3.70
(+311.1%)
Revenue Growth (YoY)
-32.5%
Share & Embed Analysis
Last updated: September 12, 2026 5:03 AM ET
Data refreshes hourly during market hours. Next update: 6:03 AM
Data refreshes hourly during market hours. Next update: 6:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SXTP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
